Olivier Molinier
Overview
Explore the profile of Olivier Molinier including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
56
Citations
5388
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Souquet P, Audigier-Valette C, Molinier O, Cortot A, Margery J, Moreau L, et al.
Lung Cancer
. 2022 Jan;
164:84-90.
PMID: 35051725
Background: Benefit from maintenance in advanced non-squamous non-small cell lung cancer (NS-NSCLC) might favor switch maintenance after disease stabilization (SD) and continuation after objective response (OR). This trial assessed a...
12.
Negre E, Coffy A, Langlais A, Daures J, Lavole A, Quoix E, et al.
JTO Clin Res Rep
. 2021 Sep;
1(1):100016.
PMID: 34589918
Introduction: This study aimed at generating a new simplified prognostic score (SPS) using common clinical and biological variables to discriminate a limited number of subgroups of patients with SCLC differing...
13.
Pinquie F, Cortot A, Chevalier L, Morel A, Sandrini J, Guguen C, et al.
Clin Lung Cancer
. 2021 Sep;
23(2):e131-e134.
PMID: 34548228
No abstract available.
14.
Cortot A, Madroszyk A, Giroux-Leprieur E, Molinier O, Quoix E, Berard H, et al.
Clin Cancer Res
. 2021 May;
27(15):4168-4176.
PMID: 34031056
Purpose: Double inhibition of epidermal growth factor receptor (EGFR) using a tyrosine kinase inhibitor plus a monoclonal antibody may be a novel treatment strategy for non-small cell lung cancer (NSCLC)....
15.
Gounant V, Duruisseaux M, Soussi G, Van Hulst S, Bylicki O, Cadranel J, et al.
Cancers (Basel)
. 2021 Apr;
13(5).
PMID: 33801285
Anti-PD-1 antibodies prolong survival of performance status (PS) 0-1 advanced non-small-cell lung cancer (aNSCLC) patients. Their efficacy in PS 3-4 patients is unknown. Conse- cutive PS 3-4 aNSCLC patients receiving...
16.
Boyer M, Sendur M, Rodriguez-Abreu D, Park K, Lee D, Cicin I, et al.
J Clin Oncol
. 2021 Jan;
39(21):2327-2338.
PMID: 33513313
Purpose: Pembrolizumab monotherapy is standard first-line therapy for metastatic non-small-cell lung cancer (NSCLC) with programmed death ligand 1 (PD-L1) tumor proportion score (TPS) ≥ 50% without actionable driver mutations. It...
17.
Herbreteau G, Langlais A, Greillier L, Audigier-Valette C, Uwer L, Hureaux J, et al.
J Clin Med
. 2020 Dec;
9(12).
PMID: 33261056
Background: The IFCT-1603 trial evaluated atezolizumab in small cell lung cancer (SCLC). The purpose of the present study was to determine whether circulating tumor DNA (ctDNA), prospectively collected at treatment...
18.
Quoix E, Audigier-Valette C, Lavole A, Molinier O, Westeel V, Barlesi F, et al.
Eur J Cancer
. 2020 Sep;
138:193-201.
PMID: 32898792
Purpose: Maintenance chemotherapy is a reasonable choice for patients with metastatic non-small cell lung carcinoma (NSCLC) not progressing after induction therapy with a platinum-based doublet. Nevertheless, there have been no...
19.
Gobbini E, Toffart A, Perol M, Assie J, Duruisseaux M, Coupez D, et al.
Clin Lung Cancer
. 2020 Jul;
21(5):e497-e510.
PMID: 32605892
Background: Immune checkpoint inhibitor (ICPi) rechallenge could represent an attractive option in non-small-cell lung cancer (NSCLC), yet no sufficient data supporting this strategy are available. This retrospective observational multicenter national...
20.
Cortot A, Audigier-Valette C, Molinier O, Moulec S, Barlesi F, Zalcman G, et al.
Eur J Cancer
. 2020 Apr;
131:27-36.
PMID: 32276179
Purpose: Second-line chemotherapy regimens have demonstrated poor benefit after failure of platinum-based chemotherapy in advanced non-squamous non-small-cell lung cancer (nsNSCLC). Methods: In this multicentre, open-label phase III trial, patients with...